Evidence map›Paper›PMID 40725039›Full record

ArticleInternational journal of molecular sciences2025

Inhibition of FOXM1 Leads to Suppression of Cell Proliferation, Migration, and Invasion Through AXL/eEF2 Kinase Signaling and Induces Apoptosis and Ferroptosis in GBM Cells.

Ezgi Biltekin, Nermin Kahraman, Ogun Ali Gul, Yasemin M Akay, Metin Akay, Bulent Ozpolat

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ezgi BiltekinDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.ORCID 0009-0002-6338-1341
Nermin KahramanDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
Ogun Ali GulDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
Yasemin M AkayDepartment of Biomedical Engineering, University of Houston, Houston, TX 77004, USA.ORCID 0000-0003-1753-6293
Metin AkayDepartment of Biomedical Engineering, University of Houston, Houston, TX 77004, USA.ORCID 0000-0002-2988-4669
Bulent OzpolatDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.

Funding

Houston Methodist Research Institute Cancer Center (61002217-70000-18300003-01)
6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is an aggressive and molecularly heterogeneous brain cancer with a poor prognosis. Despite advancements in standard-of-care therapies, including surgery, radiotherapy, and temozolomide (TMZ), the median survival remains approximately 15 months, with a 5-year survival rate of less than 10%. We and others have demonstrated that FOXM1 is a critical oncogenic driver of GBM cell proliferation. However, the role of FOXM1 and its interaction with other oncogenic signaling pathways in GBM remains incompletely understood. In this study, we identified FOXM1, AXL, and eEF2K as highly upregulated oncogenes in GBM patient tumors. We demonstrated, for the first time, that FOXM1 directly interacts with AXL and eEF2K, regulating their expression and promoting GBM cell proliferation, migration, and invasion. Knockdown of these genes disrupted cell proliferation, spheroid formation, migration, and invasion, and induced apoptosis and ferroptosis. Additionally, inhibiting the FOXM1-AXL/eEF2K signaling axis sensitized GBM cells to TMZ, further enhancing apoptotic and ferroptotic responses. These findings highlight the critical role of the FOXM1-AXL/eEF2K signaling pathway in GBM progression and suggest that targeting this axis may offer a novel multitargeted therapeutic strategy in GBM.

Indexed as

ApoptosisBrain NeoplasmsFerroptosisForkhead Box Protein M1GlioblastomaProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesAxl Receptor Tyrosine KinaseCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansNeoplasm InvasivenessSignal TransductionTemozolomideAXL protein, humanAxl Receptor Tyrosine KinaseForkhead Box Protein M1FOXM1 protein, humanProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesTemozolomideapoptosisAXLcancer stemnesseEF2KferroptosisFOXM1gene regulationglioblastoma multiforme

Identifiers

PMID40725039
PMCPMC12296191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.